Tipranavir (TPV), or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer Ingelheim under the trade name Aptivus . It is administered with ritonavir in combination therapy to treat HIV infection.
{{Drugbox | Verifiedfields = changed | verifiedrevid = 470610685 | image = File:Tipranavir structure 2.svg | image_class = skin-invert-image | width = 275 | alt =
| pronounce = | tradename = Aptivus | Drugs.com = | MedlinePlus = a606009 | licence_EU = yes | DailyMedID = Tipranavir | licence_US = Tipranavir | pregnancy_AU = B3 | pregnancy_US = C | routes_of_administration = By mouth (soft capsules) | ATC_prefix = J05 | ATC_suffix = AE09 | ATC_supplemental =
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).